Compass Pathways Announced Topline Results From An Open-label Phase 2 Study Of COMP360 Psilocybin Treatment For Post-Traumatic Stress Disorder, The Study Met Its Primary Safety Endpoint And Available Secondary Efficacy Endpoints

Benzinga · May 8 06:41

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed
Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)
81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12
Measures of symptom scores relative to baseline improved following a single 25mg dose administered with psychological support (n=22)

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Compass Pathways Announced Topline Results From An Open-label Phase 2 Study Of COMP360 Psilocybin Treatment For Post-Traumatic Stress Disorder, The Study Met Its Primary Safety Endpoint And Available Secondary Efficacy Endpoints

Risk Disclaimer